Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly Review uri icon


MeSH Major

  • Antineoplastic Agents
  • Neoplasms


  • Persons over the age of 65 years are the fastest growing segment of the U.S. population. In the next 30 years, they will comprise more than 20% of the population. Fifty percent of all cancers occur in this age group, and therefore, there is an expected rise in the total cancer burden. Data are becoming available that will better guide the use of chemotherapy in the older patient population. In this paper, information regarding age-related physiologic changes and their relationship to pharmacology, functional status, and hematopoiesis is presented. The adjuvant treatment of breast and colon cancer, as well as the primary therapy of aggressive non-Hodgkin lymphoma is reviewed. The treatment of more advanced breast, ovarian, and non-small cell lung cancer is also discussed.

publication date

  • September 2005



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.10-8-602

PubMed ID

  • 16177284

Additional Document Info

start page

  • 602

end page

  • 12


  • 10


  • 8